The effect of omega-3 fatty acids on depressive symptoms and inflammatory markers in maintenance hemodialysis patients: A randomized, placebo-controlled clinical trial

European Journal of Clinical Pharmacology

Volumn 70, Issue 6, 2014, Pages 655-665

  Gharekhani, Afshin ^a   Khatami, Mohammad Reza ^b   Dashti Khavidaki, Simin ^b,c   Razeghi, Effat ^b   Noorbala, Ahmad Ali ^c   Hashemi Nazari, Seyed Saeed ^d   Mansournia, Mohammad Ali ^b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anti inflammatory; Depression; Fish oil; Hemodialysis; Inflammation; Omega 3 fatty acids

Indexed keywords

C REACTIVE PROTEIN; DOCOSAHEXAENOIC ACID; FERRITIN; ICOSAPENTAENOIC ACID; INTERLEUKIN 10; INTERLEUKIN 6; OMEGA 3 FATTY ACID; PARATHYROID HORMONE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; DRUG COMBINATION; INTERLEUKIN DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BECK DEPRESSION INVENTORY; CHRONIC INFLAMMATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE MARKER; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; NAUSEA; PARATHYROID HORMONE BLOOD LEVEL; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT DURATION; BLOOD; CHEMISTRY; DIET SUPPLEMENTATION; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; IMMUNOLOGY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PSYCHOLOGY; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DEPRESSION; DIETARY SUPPLEMENTS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; INTERLEUKINS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; SINGLE-BLIND METHOD; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84901660677     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1666-1     Document Type: Article

References (52)

1. Noori N, Dukkipati R, Kovesdy CP, Sim JJ, Feroze U, Murali SB, Bross R, Benner D, Kopple JD, Kalantar-Zadeh K (2011) Dietary omega-3 fatty acid, ratio of omega-6 to omega-3 intake, inflammation, and survival in long-term hemodialysis patients. Am J Kidney Dis 58:248-256. doi:10.1053/j.ajkd.2011.03. 017
2. Taraz M, Khatami MR, Gharekhani A, Abdollahi A, Khalili H, Dashti-Khavidaki S (2012) Relationship between a pro- and anti-inflammatory cytokine imbalance and depression in hemodialysis patients. Eur Cytokine Netw 23:179-186. doi:10.1684/ecn.2013.0326
3. Chilcot J, Wellsted D, Farrington K (2010) Depression in end-stage renal disease: Current advances and research. Semin Dial 23:74-82. doi:10.1111/J.1525-139x.2009.0D628.x
4. Atalay H, Solak Y, Biyik M, Biyik Z, Yeksan M, Uguz F, Guney I, Tonbul HZ, Turk S (2010) Sertraline treatment is associated with an improvement in depression and health-related quality of life in chronic peritoneal dialysis patients. Int Urol Nephrol 42:527-536. doi:10.1007/s11255-0D9-9686-y
5. Tossani E, Cassano P, Fava M (2005) Depression and renal disease. Semin Dial 18:73-81
6. Kalender B, Ozdemir AC, Koroglu G (2006) Association of depression with markers of nutrition and inflammation in chronic kidney disease and end-stage renal disease. Nephron Clin Pract 102:c115-c121
7. Kimmel PL, Cukor D, Cohen SD, Peterson RA (2007) Depression in end-stage renal disease patients: A critical review. Adv Chronic Kidney Dis 14:328-334
8. Simic Ogrizovic S, Jovanovic D, Dopsaj V, Radovic M, Sumarac Z, Bogavac SN, Stosovic M, Stanojevic M, Nesic V (2009) Could depression be a new branch of MIA syndrome? Clin Nephrol 71:164-172
9. Sutcigil L, Oktenli C, Musabak U, Bozkurt A, Consever A, Uzun O, Sanisoglu Y, Yesilova Z, Ozmeneler N, Ozsahin A, Sengul A (2007) Pro- and anti-inflammatory cytokine balance in major depression: Effect of sertraline therapy. Clin Dev Immunol 76396:1-6. doi:10.1155/2007/76396
10. Perunicic-Pekovic GB, Rasic ZR, Pljesa SI, Sobajic SS, Djuricic I, Maletic R, Ristic-Medic DK (2007) Effect of n-3 fatty acids on nutritional status and inflammatory markers in hemodialysis patients. Nephrology (Carlton) 12:331-336
11. Tajalizadekhoob Y, Sharifi F, Fakhrzadeh H, Mirarefin M, Ghaderpanahi M, Badamchizade Z, Azimipour S (2011) The effect of low-dose omega 3 fatty acids on the treatment of mild to moderate depression in the elderly: a double-blind, randomized, placebo-controlled study. Eur Arch Psychiatry Clin Neurosci 261:539-549. doi:10.1007/S00408-D11-0191-9
12. Dinan T, Siggins L, Scully P, O'Brien S, Ross P, Stanton C (2009) Investigating the inflammatory phenotype of major depression: Focus on cytokines and polyunsaturated fatty acids. J Psychiatr Res 43:471-476. doi:10.1016/j.jpsychires.2008.06.003
13. Watnick S, Wang PL, Demadura T, Ganzini L (2005) Validation of 2 depression screening tools in dialysis patients. Am J Kidney Dis 46:919-924
14. Hedayati SS, Bosworth HB, Kuchibhatla M, Kimmel PL, Szczech LA (2006) The predictive value of self-report scales compared with physician diagnosis of depression in hemodialysis patients. Kidney Int 69:1662-1668
15. Craven JL, Rodin JM, Littlefield C (1988) The beck depression inventory as a screening device for major depression in renal dialysis patients. Int J Psychiatry Med 18:365-374
16. Ghassemzadeh H, Mojtabai R, Karamghadiri N, Ebrahimkhani N (2005) Psychometric properties of a Persian-language version of the Beck Depression Inventory-second edition: BDI-II-Persian. Depress Anxiety 21:185-192
17. Finkelstein FO, Finkelstein SH (2000) Depression in chronic dialysis patients: assessment and treatment. Nephrol Dial Transplant 15:1911-1913
18. Hibbeln JR, Salem N (1995) Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy. Am J Clin Nutr 62:1-9
19. Jadoon A, Chiu CC, McDermott L, Cunningham P, Frangou S, Chang CJ, Sun IW, Liu SI, Lu ML, Su KP, Huang SY, Stewart R (2012) Associations of polyunsaturated fatty acids with residual depression or anxiety in older people with major depression. J Affect Disord 136:918-925. doi:10.1016/j/jad.2011.09. 007
20. Grenyer BFS, Crowe T, Meyer B, Owen AJ, Grigonis-Deane EM, Caputi P, Howe PR (2007) Fish oil supplementation in the treatment of major depression: A randomized double-blind placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 31:1393-1396
21. Chalon S (2006) Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukot Essent Fat Acids 75:259-269
22. 2 activity: Their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol Rev 58:591-620
23. Pottala JV, Talley JA, Churchill SW, Lynch DA, von Schacky C, Harris WS (2012) Red blood cell fatty acids are associated with depression in a case-control study of adolescents. Prostaglandins Leukot Essent Fat Acids 86:161-165. doi:10.1016/j.plefa.2012.03.002
24. Adams PB, Lawson S, Sanigorski A, Sinclair AJ (1996) Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids Suppl 31:S157-S161
25. Conklin SM, Manuck SB, Yao JK, Flory JD, Hibbeln JR, Muldoon MF (2007) High ω-6 and low ω-3 fatty acids are associated with depressive symptoms and neuroticism. Psychosom Med 69:932-934
26. Szklarek-Kubicka M, Fijałkowska-Morawska J, Zaremba-Drobnik D, Uciński A, Czekalski S, Nowicki M (2009) Effect of intradialytic intravenous administration of ω-3 fatty acids on nutritional status and inflammatory response in hemodialysis patients: A pilot study. J Ren Nutr 19:487-493. doi:10.1053/j.jrn.2009.05.007
27. Saifullah A, Watkins BA, Saha C, Li Y, Moe SM, Friedman AN (2007) Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients-a pilot study. Nephrol Dial Transplant 22:3561-3567
28. Sinn N, Milte CM, Street SJ, Buckley JD, Coates AM, Petkov J, Howe PR (2012) Effects of n-3 fatty acids, EPAv. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomized controlled trial. Br J Nutr 107:1682-1693. doi:10.1017/s0007114511004788
29. Rizzo AM, Corsetto PA, Montorfano G, Opizzi A, Faliva M, Giacosa A, Ricevuti G, Pelucchi C, Berra B, Rondanelli M (2012) Comparison between the AA/EPA ratio in depressed and non depressed elderly females: omega-3 fatty acid supplementation correlates with improved symptoms but does not change immunological parameters. Nutr J 82:1-11. doi:10.1186/1475-2891-11-82
30. Mischoulon D, Papakostas GI, Dording CM, Farabaugh AH, Sonawalla SB, Agoston AM, Smith J, Beaumont EC, Dahan LE, Alpert JE, Nierenberg AA, Fava M (2009) A double-blind randomized controlled trial of ethyl-eicosapentaenoate (EPA-E) for major depressive disorder. J Clin Psychiatry 70:1636-1644. doi:10.4088/JCP.08m04603
31. Kraguljac NV, Montori VM, Pavuluri M, Chai HS, Wilson BS, Unal SS (2009) Efficacy of omega-3 fatty acids in mood disorders - a systematic review and metaanalysis. Psychopharmacol Bull 42:39-54
32. Martins JG (2009) EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J Am Coll Nutr 28:525-542
33. Appleton KM, Rogers PJ, Ness AR (2010) Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr 91:757-770. doi:10.3945/ajcn.2009.28313
34. Bloch MH, Hannestad J (2012) Omega-3 fatty acids for the treatment of depression: Systematic review and meta-analysis. Mol Psychiatry 17:1272-1282. doi:10.1038/mp.2011.100
35. Sublette ME, Ellis SP, Geant AL, Mann JJ (2011) Meta-analysis: Effects of eicosapentaenoic acid in clinical trials in depression. J Clin Psychiatry 72:1577-1584. doi:10.4088/JCP.10m06634
36. Martins JG, Bentsen H, Puri BK (2012) Eicosapentaenoic acid appears to be the key omega-3 fatty acid component associated with efficacy in major depressive disorder: a critique of Bloch and Hannestad and updated meta-analysis. Mol Psychiatry 17:1144-1149. doi:10.1038/mp.2012.25
37. Jazayeri S, Tehrani-Doost M, Keshavarz SA, Hosseini M, Djazayeri A, Amini H, Jalali M, Peet M (2008) Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust N Z J Psychiatry 42:192-198. doi:10.1080/00048670701827275
38. Gertsik L, Poland RE, Bresee C, Rapaport MH (2012) Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. J Clin Psychopharmacol 32:61-64. doi:10.1097/JCP.0b013e31823f3b5f
39. Basterzi AD, Aydemir C, Kisa C, Aksaray S, Tuzer V, Yazici K, Göka E (2005) IL-6 levels decrease with SSRI treatment in patients with major depression. Hum Psychopharmacol 20:473-476
40. Kubera M, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M (2001) Anti-inflammatory effects of antidepressants through suppression of the interferon-γ/interleukin-10 production ratio. J Clin Psychopharmacol 21:199-206
41. Rasic-Milutinovic Z, Perunicic G, Pljesa S, Gluvic Z, Sobajic S, Djuric I, Ristic D (2007) Effects of N-3 PUFAs supplementation on insulin resistance and inflammatory biomarkers in hemodialysis patients. Ren Fail 29:321-329
42. Himmelfarb J, Phinney S, Ikizler TA, Kane J, McMonagle E, Miller G (2007) Gamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patients. J Ren Nutr 17:296-304
43. Janssen DGA, Caniato RN, Verster JC, Baune BT (2010) A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol 25:201-215. doi:10.1002/hup.1103
44. Hegarty B, Parker G (2013) Fish oil as a management component for mood disorders - an evolving signal. Curr Opin Psychiatry 26:33-40. doi:10.1097/YCO.0b013e32835ab4a7
45. Bowden RG, Wilson RL, Deike E, Gentile M (2009) Fish oil supplementation lowers C-reactive protein levels independent of triglyceride reduction in patients with end-stage renal disease. Nutr Clin Pract 24:508-512. doi:10.1177/0884533609335376
46. Yeun JY, Levine RA, Mantadilok V, Kaysen GA (2000) C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 35:469-476
47. Montinaro V, Laffaldano GP, Granata S, Porcelli P, Todarello O, Schena FP, Pertosa G (2010) Emotional symptoms, quality of life and cytokine profile in hemodialysis patients. Clin Nephrol 73:36-43
48. Dervisoglu E, Kir HM, Kalender B, Eraldemir C, Caglayan C (2008) Depressive symptoms and proinflammatory cytokine levels in chronic renal failure patients. Nephron Clin Pract 108:c272-c277. doi:10.1159/000126907
49. Kalender B, Dervisoglu E, Sengul E, Ozdemir AC, Akhan SC, Yalug I, Uzun H (2007) Depression, nutritional status, and serum cytokines is peritoneal dialysis patients: Is there a relationship? Perit Dial Int 27:593-595
50. Knuth B, Radtke V, Rocha P, da Silva KS, Dalsóglio F, Gazal M, Jansen K, Souza DO, Portela LV, Kaster M, Oses JP (2013) Prevalence of depression symptoms and serum levels of interleukin-6 in hemodialysis patients. Psychiatry Clin Neurosci. doi:10.1111/pcn.12130
51. Friedman A, Moe S (2006) Review of the effects of omega-3 supplementation in dialysis patients. Clin J Am Soc Nephrol 1:182-192
52. Madsen T, Christensen JH, Svensson M, Witt PM, Toft E, Schmidt EB (2011) Marine n-3 polyunsaturated fatty acids in patients with end-stage renal failure and in subjects without kidney disease: a comparative study. J Ren Nutr 21:169-175. doi:10.1053/j.jrn.2010.06.020